FDA Approves Teva Pharmaceutical Industries Limited's Generic Version of Roche's Xeloda

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of Roche Holding AG's cancer drug Xeloda. Teva Pharmaceuticals USA, a unit of the generic drugmaker, will market 150 and 500 milligram doses of the oral drug, named capecitabine. The drug, like Xeloda, will have a boxed warning about an increased risk of bleeding in patients who are on blood thinners .

Help employers find you! Check out all the jobs and post your resume.

Back to news